Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation
NCT02867384Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2016
- Primary completion
- Nov 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in graft-versus-host disease (GVHD), sponsored by Dana-Farber Cancer Institute. Started Nov 2016; status: completed.
02
Drugs
obinutuzumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02867384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02867384.